Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2007
已完成
2
100.0%
暂无批准数据
- Citius Oncology has finalized a distribution agreement with McKesson Corporation, completing its U.S. distribution network for LYMPHIR (denileukin diftitox-cxdl) with all three largest pharmaceutical distributors in the country. - The partnership positions LYMPHIR for its planned fourth quarter 2025 commercial launch, targeting the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. - LYMPHIR received FDA approval in August 2024 as a targeted immunotherapy that combines IL-2 receptor binding with diphtheria toxin fragments to selectively kill cancer cells expressing IL-2 receptors. - Management estimates the initial market for LYMPHIR exceeds $400 million and is underserved by existing therapies, with the drug carrying significant safety warnings including a boxed warning for capillary leak syndrome.
- DelveInsight's 2025 pipeline assessment reveals three key companies are developing novel hemorrhoids treatment therapies, with emerging drugs like EB02, Halo-Lido, and Hydrocortisone Acetate Suppository expected to significantly impact the market. - Citius Pharmaceuticals completed a Phase 2b trial for Halo-Lido (CITI-002) in 2023 and applied for patents in June 2023, positioning the topical formulation as a promising treatment for hemorrhoid relief. - The hemorrhoids treatment market faces growth drivers including rising awareness and increased reported cases, while barriers include lack of specialized healthcare infrastructure and time-consuming treatment procedures.
- Citius Pharmaceuticals completed a $15.8 million registered direct offering with $6 million raised upfront and potential additional $9.8 million from warrant exercises. - The company plans to use proceeds to support the commercial launch of LYMPHIR, an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma. - The offering included 4.92 million shares at $1.22 per share with accompanying warrants exercisable at $1.00 per share over 24 months. - Citius maintains a late-stage pipeline including Mino-Lok for catheter-related infections and CITI-002 for hemorrhoid treatment, both having completed pivotal trials.
- Citius Oncology has entered into a distribution services agreement with Cardinal Health to support the upcoming U.S. commercial launch of LYMPHIR for cutaneous T-cell lymphoma treatment. - LYMPHIR is an FDA-approved targeted immunotherapy indicated for adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. - The partnership leverages Cardinal Health's proven specialty pharmaceutical distribution capabilities to ensure efficient and reliable access to LYMPHIR for healthcare providers and patients. - Management estimates the initial market for LYMPHIR currently exceeds $400 million and is underserved by existing therapies.
- Citius Oncology is considering strategic alternatives, including partnerships and acquisitions, after FDA approval of Lymphir for relapsed or refractory cutaneous T-cell lymphoma (CTCL). - Lymphir, targeting the interleukin-2 (IL-2) receptor, is the first drug specifically for CTCL and aims to address an underserved market estimated at over $400 million. - Citius plans to launch Lymphir in the first half of the year, focusing on manufacturing, marketing, reimbursement, and sales, while also exploring expanded indications and international partnerships. - Citius Pharmaceuticals is also advancing Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections, following positive Phase 3 trial results.
- Citius Pharmaceuticals completed a Type C meeting with the FDA to discuss the Phase 3 Mino-Lok program for catheter-related bloodstream infections (CRBSI). - The FDA provided clear and actionable guidance, supporting a potential New Drug Application (NDA) submission for Mino-Lok. - Mino-Lok, if approved, would be the first FDA-approved treatment to salvage central venous catheters, potentially reducing healthcare costs and improving patient outcomes. - Citius Pharma is committed to advancing the Mino-Lok program and will provide updates on regulatory and clinical developments.
- Citius Pharmaceuticals received constructive feedback from the FDA regarding its Phase 3 Mino-Lok program, aimed at salvaging central venous catheters in patients with CLABSI. - The FDA's guidance supports a potential New Drug Application (NDA) submission for Mino-Lok, addressing critical aspects like in-vitro data, clinical efficacy, safety, and regulatory considerations. - Mino-Lok, combining minocycline, ethanol, and edetate disodium, offers a novel approach to treating catheter-related bloodstream infections, potentially reducing healthcare costs and improving patient outcomes. - Citius Pharma is committed to advancing the Mino-Lok program and will provide updates on regulatory and clinical developments.
- Citius Pharmaceuticals reports a productive Type C meeting with the FDA regarding its Mino-Lok program for catheter-related bloodstream infections (CRBSI). - The FDA provided clear and actionable guidance, supporting a potential New Drug Application (NDA) submission for Mino-Lok. - Mino-Lok demonstrated compelling clinical outcomes in a Phase 3 trial, offering a potential alternative to catheter removal and reducing healthcare costs. - Citius Pharma is committed to advancing the Mino-Lok program and will provide updates on regulatory and clinical developments.
- A clinical trial combining Lymphir with Keytruda demonstrated a 33% clinical benefit rate and a 27% overall response rate in lymphoma patients with extensive prior treatment history. - Patients who benefited from the Lymphir-Keytruda combination experienced a median progression-free survival of 57 weeks, indicating a substantial improvement in outcomes. - The combination therapy exhibited a favorable safety profile, with most adverse events attributed to the underlying disease rather than the treatment itself. - Analysts from Maxim Group and H.C. Wainwright have reiterated a Buy rating on Citius Pharmaceuticals (CTXR) with a $4.00 price target, citing the promising clinical data.
- A Phase 1 trial combining LYMPHIR and pembrolizumab shows a 27% objective response rate in patients with recurrent solid tumors, particularly gynecological malignancies. - The chemotherapy-free regimen demonstrated a 33% clinical benefit rate, with a median progression-free survival of 57 weeks in patients who experienced clinical benefit. - The combination therapy was well-tolerated, with no significant immune-related adverse events, suggesting LYMPHIR may enhance pembrolizumab's anti-tumor activity. - Citius Oncology plans to expand research into a Phase 2 study to evaluate the combination's benefits across a broader range of solid tumor types.
